Page last updated: 2024-11-12

sideroxylonal c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sideroxylonal C: formylated phloroglucinol from flowers of Eucalyptus albens; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
EucalyptusgenusA genus of trees of the Myrtaceae family, native to Australia, that yields gums, oils, and resins which are used as flavoring agents, astringents, and aromatics.[MeSH]MyrtaceaeThe myrtle plant family of the order Myrtales. It includes several aromatic medicinal plants such as EUCALYPTUS.[MeSH]

Cross-References

ID SourceID
PubMed CID10413640
CHEMBL ID453538
MeSH IDM0302831

Synonyms (4)

Synonym
bdbm50241601
CHEMBL453538 ,
sideroxylonal c
(2r,3r,4r)-2-(3,5-diformyl-2,4,6-trihydroxyphenyl)-5,7-dihydroxy-4-(2-methylpropyl)-3-propan-2-yl-3,4-dihydro-2h-chromene-6,8-dicarbaldehyde
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Plasminogen activator inhibitor 1Homo sapiens (human)IC50 (µMol)4.70000.09104.892810.0000AID378705
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
angiogenesisPlasminogen activator inhibitor 1Homo sapiens (human)
regulation of signaling receptor activityPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of plasminogen activationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of endopeptidase activityPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of smooth muscle cell migrationPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of blood coagulationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of blood coagulationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of cell migrationPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of interleukin-8 productionPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of leukotriene production involved in inflammatory responsePlasminogen activator inhibitor 1Homo sapiens (human)
fibrinolysisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of angiogenesisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of receptor-mediated endocytosisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of inflammatory responsePlasminogen activator inhibitor 1Homo sapiens (human)
defense response to Gram-negative bacteriumPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of fibrinolysisPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of vascular wound healingPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of wound healingPlasminogen activator inhibitor 1Homo sapiens (human)
cellular response to lipopolysaccharidePlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of monocyte chemotaxisPlasminogen activator inhibitor 1Homo sapiens (human)
replicative senescencePlasminogen activator inhibitor 1Homo sapiens (human)
dentinogenesisPlasminogen activator inhibitor 1Homo sapiens (human)
positive regulation of odontoblast differentiationPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of smooth muscle cell-matrix adhesionPlasminogen activator inhibitor 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic processPlasminogen activator inhibitor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
protease bindingPlasminogen activator inhibitor 1Homo sapiens (human)
serine-type endopeptidase inhibitor activityPlasminogen activator inhibitor 1Homo sapiens (human)
signaling receptor bindingPlasminogen activator inhibitor 1Homo sapiens (human)
protein bindingPlasminogen activator inhibitor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
collagen-containing extracellular matrixPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular regionPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular spacePlasminogen activator inhibitor 1Homo sapiens (human)
plasma membranePlasminogen activator inhibitor 1Homo sapiens (human)
platelet alpha granule lumenPlasminogen activator inhibitor 1Homo sapiens (human)
collagen-containing extracellular matrixPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular exosomePlasminogen activator inhibitor 1Homo sapiens (human)
serine protease inhibitor complexPlasminogen activator inhibitor 1Homo sapiens (human)
peptidase inhibitor complexPlasminogen activator inhibitor 1Homo sapiens (human)
extracellular spacePlasminogen activator inhibitor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID378705Inhibition of human PAI1 using tissue type plasminogen activator substrate by plasmon resonance1999Journal of natural products, Feb, Volume: 62, Issue:2
Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's5 (45.45)29.6817
2010's5 (45.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]